PMID: 3769764Oct 1, 1986Paper

Therapy of choice for the empiric treatment of the febrile neutropenic patient

Drug Intelligence & Clinical Pharmacy
S L Barriere

Abstract

Patients who become neutropenic secondary to chemotherapy for malignancy are at high risk for bacterial infection. Since the most common organisms include enteric gram-negative bacilli and staphylococci, drug combinations have traditionally been used. In addition, available clinical evidence suggests that synergistic drug combinations are most effective in the treatment of infections due to Pseudomonas aeruginosa. Comparative clinical trials have not shown any particular drug combination to be superior to others tested. Therefore, the drug choice for the combination should be based on local susceptibility patterns, clinical experience, and cost. Newer beta-lactam compounds are broader in spectrum and more potent than older drugs, and have been tested as sole agents in this setting. Although results appear promising for drugs such as cefoperazone or ceftazidime, the development of resistance and lack of adequate antistaphylococcal activity preclude routine use of these drugs. Imipenem is currently undergoing clinical trials for this purpose and appears to have the appropriate breadth of spectrum. However, frequent development of resistance among isolates of P. aeruginosa is problematic. At the present time a combination of an am...Continue Reading

References

Oct 1, 1985·Annals of Internal Medicine·M Barza
Mar 1, 1983·Reviews of Infectious Diseases·R BolivarG P Bodey
Nov 1, 1982·The Journal of Antimicrobial Chemotherapy·R D Lawson, R C Baskin
Mar 1, 1983·Reviews of Infectious Diseases·J Klastersky
Mar 1, 1984·The American Journal of Medicine·P A PizzoK J Robichaud
Aug 1, 1980·Antimicrobial Agents and Chemotherapy·J C WadeP H Wiernik
Sep 1, 1984·The American Journal of Medicine·D J WinstonR P Gale

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.